BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 29246495)

  • 1. Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients.
    Lee S; Bazick H; Chittoor-Vinod V; Al Salihi MO; Xia G; Notterpek L
    Am J Pathol; 2018 Mar; 188(3):728-738. PubMed ID: 29246495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs.
    Hanemann CO; Gabreëls-Festen AA; Stoll G; Müller HW
    Acta Neuropathol; 1997 Oct; 94(4):310-5. PubMed ID: 9341930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
    Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
    J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PMP22 expression in dermal nerve myelin from patients with CMT1A.
    Katona I; Wu X; Feely SM; Sottile S; Siskind CE; Miller LJ; Shy ME; Li J
    Brain; 2009 Jul; 132(Pt 7):1734-40. PubMed ID: 19447823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical characterization of protein quality control mechanisms during disease progression in the C22 mouse model of CMT1A.
    Chittoor VG; Sooyeon L; Rangaraju S; Nicks JR; Schmidt JT; Madorsky I; Narvaez DC; Notterpek L
    ASN Neuro; 2013 Dec; 5(5):e00128. PubMed ID: 24175617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducible HSP70 is critical in preventing the aggregation and enhancing the processing of PMP22.
    Chittoor-Vinod VG; Lee S; Judge SM; Notterpek L
    ASN Neuro; 2015; 7(1):. PubMed ID: 25694550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies.
    Svaren J; Moran JJ; Wu X; Zuccarino R; Bacon C; Bai Y; Ramesh R; Gutmann L; Anderson DM; Pavelec D; Shy ME
    Ann Neurol; 2019 Jun; 85(6):887-898. PubMed ID: 30945774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression.
    Fortun J; Go JC; Li J; Amici SA; Dunn WA; Notterpek L
    Neurobiol Dis; 2006 Apr; 22(1):153-64. PubMed ID: 16326107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low affinity NGF receptor expression in CMT1A nerve biopsies of different disease stages.
    Hanemann CO; Gabreëls-Fasten AA; Müller HW; Stoll G
    Brain; 1996 Oct; 119 ( Pt 5)():1461-9. PubMed ID: 8931571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene dosage effects in hereditary peripheral neuropathy. Expression of peripheral myelin protein 22 in Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies nerve biopsies.
    Gabriel JM; Erne B; Pareyson D; Sghirlanzoni A; Taroni F; Steck AJ
    Neurology; 1997 Dec; 49(6):1635-40. PubMed ID: 9409359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct relationship between increased expression and mistrafficking of the Charcot-Marie-Tooth-associated protein PMP22.
    Marinko JT; Carter BD; Sanders CR
    J Biol Chem; 2020 Aug; 295(34):11963-11970. PubMed ID: 32647009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral myelin protein 22 gene duplication with atypical presentations: a new example of the wide spectrum of Charcot-Marie-Tooth 1A disease.
    Mathis S; Corcia P; Tazir M; Camu W; Magdelaine C; Latour P; Biberon J; Guennoc AM; Richard L; Magy L; Funalot B; Vallat JM
    Neuromuscul Disord; 2014 Jun; 24(6):524-8. PubMed ID: 24792522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrastructural distribution of PMP22 in Charcot-Marie-Tooth disease type 1A.
    Haney C; Snipes GJ; Shooter EM; Suter U; Garcia C; Griffin JW; Trapp BD
    J Neuropathol Exp Neurol; 1996 Mar; 55(3):290-9. PubMed ID: 8786387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the Pathogenesis of Charcot-Marie-Tooth Disease Type 1A Using Patient-Specific iPSCs.
    Shi L; Huang L; He R; Huang W; Wang H; Lai X; Zou Z; Sun J; Ke Q; Zheng M; Lu X; Pei Z; Su H; Xiang AP; Li W; Yao X
    Stem Cell Reports; 2018 Jan; 10(1):120-133. PubMed ID: 29276154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease.
    Nobbio L; Vigo T; Abbruzzese M; Levi G; Brancolini C; Mantero S; Grandis M; Benedetti L; Mancardi G; Schenone A
    Neurobiol Dis; 2004 Jun; 16(1):263-73. PubMed ID: 15207283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
    Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
    Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of one induced pluripotent stem cell line JUCGRMi004-A from a Charcot-Marie-Tooth disease type 1A (CMT1A) patient with PMP22 duplication.
    Liu X; Ishikawa KI; Hattori N; Akamatsu W
    Stem Cell Res; 2024 Jun; 77():103401. PubMed ID: 38537501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of Charcot-Marie-Tooth 1A (CMT1A) neuropathy.
    Hanemann CO; Müller HW
    Trends Neurosci; 1998 Jul; 21(7):282-6. PubMed ID: 9683317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An essential role of MAG in mediating axon-myelin attachment in Charcot-Marie-Tooth 1A disease.
    Kinter J; Lazzati T; Schmid D; Zeis T; Erne B; Lützelschwab R; Steck AJ; Pareyson D; Peles E; Schaeren-Wiemers N
    Neurobiol Dis; 2013 Jan; 49():221-31. PubMed ID: 22940629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.
    Lee JS; Lee JY; Song DW; Bae HS; Doo HM; Yu HS; Lee KJ; Kim HK; Hwang H; Kwak G; Kim D; Kim S; Hong YB; Lee JM; Choi BO
    Nucleic Acids Res; 2020 Jan; 48(1):130-140. PubMed ID: 31713617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.